Lung cancer remains one of the most common and serious cancers worldwide. For many years, treatment options were limited to surgery, chemotherapy, and radiation therapy. While these treatments are still essential, especially in early-stage disease, outcomes for advanced lung cancer were historically poor. Over the past decade, immunotherapy has dramatically changed how lung cancer is treated, offering new hope for many patients.
Understanding the immunotherapy success rate for lung cancer can be confusing, as success does not always mean cure or immediate tumor disappearance. Instead, immunotherapy works by helping the immune system recognize and attack cancer cells, often leading to long-lasting disease control in a subset of patients. This article explains how immunotherapy works in lung cancer, what success rates look like in different situations, who benefits the most, and what patients can realistically expect.
Read About Immunotherapy for Lung Cancer on OncoDaily
How Immunotherapy Works in Lung Cancer
The most commonly used immunotherapy drugs for lung cancer are called immune checkpoint inhibitors, including pembrolizumab, nivolumab, atezolizumab, and durvalumab. These drugs target proteins such as PD-1 or PD-L1, which cancer cells use to hide from the immune system. By blocking these signals, immunotherapy allows immune cells to recognize and attack lung cancer cells more effectively.
Immunotherapy is most widely used in non–small cell lung cancer (NSCLC), which accounts for about 85% of lung cancer cases. It is also used in small cell lung cancer (SCLC), usually in combination with chemotherapy.
What Does “Success Rate” Mean in Lung Cancer Immunotherapy?
When patients ask about the immunotherapy success rate for lung cancer, doctors usually look at several measures:
- Tumor response rate, meaning how often tumors shrink
- Progression-free survival, meaning how long the cancer stays under control
- Overall survival, meaning how long patients live after starting treatment
- Durability of response, meaning how long benefits last
Unlike chemotherapy, immunotherapy may not work for everyone, but when it does work, responses can last much longer.
Immunotherapy Success Rate in Non–Small Cell Lung Cancer
In advanced non–small cell lung cancer, immunotherapy has become a standard first-line treatment for many patients.
In major clinical trials such as KEYNOTE-024 and KEYNOTE-042, patients with high PD-L1 expression (PD-L1 ≥50%) treated with pembrolizumab alone experienced response rates of about 40–45%, with significant improvements in overall survival compared with chemotherapy (Reck et al., 2016; Mok et al., 2019). Some patients lived several years longer than expected, and a portion remained alive beyond five years.
For patients with lower PD-L1 expression, immunotherapy combined with chemotherapy is often used. In these studies, response rates typically range from 45% to 60%, higher than chemotherapy alone, and survival outcomes are clearly improved (Gandhi et al., 2018).
Overall, across different treatment settings, the immunotherapy success rate for lung cancer in NSCLC ranges from about 20% to over 50%, depending on tumor biology, treatment approach, and patient characteristics.
Long-Term Survival: Why Immunotherapy Is Different
One of the most important differences between immunotherapy and older treatments is long-term survival. With chemotherapy, benefits usually last only a few months. With immunotherapy, a subset of patients experience durable responses lasting years.
Follow-up analyses from trials such as KEYNOTE-001 and CheckMate 017/057 show that approximately 15–20% of patients with advanced NSCLC are alive five years after starting immunotherapy, something that was extremely rare before these treatments became available (Gettinger et al., 2018). This long-term benefit is a major reason immunotherapy has changed expectations for lung cancer outcomes.
Immunotherapy Success Rate in Small Cell Lung Cancer
Small cell lung cancer is more aggressive and grows faster than NSCLC. Immunotherapy is usually given together with chemotherapy.
In trials such as IMpower133 and CASPIAN, adding immunotherapy to chemotherapy improved survival compared with chemotherapy alone. Response rates range from 60–70%, largely driven by chemotherapy, but immunotherapy helps extend survival and maintain disease control longer (Horn et al., 2018; Paz-Ares et al., 2019). Although long-term survival remains limited in SCLC, immunotherapy has modestly but meaningfully improved outcomes.
Who Benefits Most From Immunotherapy for Lung Cancer?
The success of immunotherapy depends on several factors. Patients with high PD-L1 expression are more likely to respond, especially to immunotherapy alone. Those with a history of smoking tend to respond better than never-smokers, likely due to higher tumor mutation burden. Patients without certain genetic mutations—such as EGFR or ALK alterations—generally benefit more from immunotherapy than those with these driver mutations, who are often treated with targeted therapies instead. Overall health, immune function, and the absence of severe autoimmune disease also influence outcomes.
Does Immunotherapy Cure Lung Cancer?
For most patients, immunotherapy is not a cure, especially in advanced disease. However, a small percentage of patients achieve long-term remission, meaning the cancer remains controlled for years with little or no evidence of progression. In early-stage lung cancer, immunotherapy given before or after surgery is now improving cure rates, and this is an area of active research.
Read About Lung Cancer Cure Rate on OncoDaily
Side Effects and Quality of Life
Immunotherapy is generally better tolerated than chemotherapy, but it can cause immune-related side effects. These may include fatigue, skin rash, thyroid problems, diarrhea, or inflammation of organs such as the lungs or liver. Most side effects are manageable when detected early, and many patients maintain a good quality of life during treatment.
Importantly, many patients report feeling better on immunotherapy than they did on chemotherapy, particularly after the first few months of treatment.
What Patients Should Discuss With Their Oncologist
Patients should talk with their oncology team about:
- PD-L1 testing results
- Whether immunotherapy alone or with chemotherapy is appropriate
- Expected benefits based on their specific cancer type
- Possible side effects and how they are monitored
- Availability of clinical trials
Understanding how the immunotherapy success rate for lung cancer applies to an individual diagnosis helps patients make informed treatment decisions.
Key Takeaway for Patients
Immunotherapy has transformed lung cancer treatment. While it does not work for everyone, the immunotherapy success rate for lung cancer is significantly higher than older treatments for many patients, and those who respond may experience long-lasting benefits and improved survival. For the right patient, immunotherapy offers real hope, longer life, and better quality of life than was possible just a decade ago.
You Can Watch More on OncoDaily Youtube TV
Written by Armen Gevorgyan, MD